{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:41:12Z","timestamp":1771659672986,"version":"3.50.1"},"reference-count":40,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0053","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T12:47:17Z","timestamp":1717505237000},"source":"Crossref","is-referenced-by-count":2,"title":["An online decision aid for patients with metastatic melanoma\u2014results of the randomized controlled trial \u201ePEF-Immun\u201c"],"prefix":"10.3238","author":[{"given":"Pia","family":"Grabbe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena S.","family":"Borchers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin M.","family":"Gschwendtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Strobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marietta","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"K\u00e4lber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rendon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Bieber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"10.3238\/arztebl.m2024.0053_ref1","unstructured":"AWMF: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge des Melanoms (2020). www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Melanom\/Melanom_Version_3\/LL_Melanom_Langversion_3.3.pdf (last accessed on 19 January 2024)."},{"key":"10.3238\/arztebl.m2024.0053_ref2","doi-asserted-by":"crossref","unstructured":"Hassel JC: Ipilimumab plus nivolumab for advanced melanoma. Lancet Oncol 2016; 17: 1471\u20132","DOI":"10.1016\/S1470-2045(16)30409-0"},{"key":"10.3238\/arztebl.m2024.0053_ref3","doi-asserted-by":"crossref","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23\u201334.","DOI":"10.1056\/NEJMoa1504030"},{"key":"10.3238\/arztebl.m2024.0053_ref4","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al.: Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol 2022; 40: 127\u201337","DOI":"10.1200\/JCO.21.02229"},{"key":"10.3238\/arztebl.m2024.0053_ref5","doi-asserted-by":"crossref","unstructured":"Robert C, Schachter J, Long GV, et al.: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521\u201332","DOI":"10.1056\/NEJMoa1503093"},{"key":"10.3238\/arztebl.m2024.0053_ref6","doi-asserted-by":"crossref","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535\u201346","DOI":"10.1056\/NEJMoa1910836"},{"key":"10.3238\/arztebl.m2024.0053_ref7","doi-asserted-by":"crossref","unstructured":"Wang DY, Salem JE, Cohen JV, et al.: Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 1721\u20138","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"10.3238\/arztebl.m2024.0053_ref8","doi-asserted-by":"crossref","unstructured":"Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949\u201354","DOI":"10.1038\/nature00766"},{"key":"10.3238\/arztebl.m2024.0053_ref9","doi-asserted-by":"crossref","unstructured":"Long GV, Stroyakovskiy D, Gogas H, et al.: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444\u201351","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"10.3238\/arztebl.m2024.0053_ref10","doi-asserted-by":"crossref","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, et al.: Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867\u201376","DOI":"10.1056\/NEJMoa1408868"},{"key":"10.3238\/arztebl.m2024.0053_ref11","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Dr\u00e9no B, Larkin J, et al.: 5-year outcomes with cobimetinib plus vin BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res 2021; 27: 5225\u201335","DOI":"10.1158\/1078-0432.CCR-21-0809"},{"key":"10.3238\/arztebl.m2024.0053_ref12","doi-asserted-by":"crossref","unstructured":"Dummer R, Flaherty KT, Robert C, et al.: COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol 2022; 40: 4178\u201388","DOI":"10.1200\/JCO.21.02659"},{"key":"10.3238\/arztebl.m2024.0053_ref13","doi-asserted-by":"crossref","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, et al.: Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 2019; 381: 626\u201336","DOI":"10.1056\/NEJMoa1904059"},{"key":"10.3238\/arztebl.m2024.0053_ref14","doi-asserted-by":"crossref","unstructured":"Heinzerling L, Eigentler TK, Fluck M, et al.: Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019; 4: e000491","DOI":"10.1136\/esmoopen-2019-000491"},{"key":"10.3238\/arztebl.m2024.0053_ref15","doi-asserted-by":"crossref","unstructured":"Albrecht KJ, Nashan D, Meiss F, Bengel J, Reuter K: Shared decision making in dermato-oncology: preference for involvement of melanoma patients. Melanoma Res 2014; 24: 68\u201374","DOI":"10.1097\/CMR.0000000000000030"},{"key":"10.3238\/arztebl.m2024.0053_ref16","doi-asserted-by":"crossref","unstructured":"Br\u00fctting J, Bergmann M, Garzarolli M, et al.: Information-seeking and use of information resources among melanoma patients of German skin cancer centers. J Dtsch Dermatol Ges 2018; 16: 1093\u20131101.","DOI":"10.1111\/ddg.13630"},{"key":"10.3238\/arztebl.m2024.0053_ref17","doi-asserted-by":"crossref","unstructured":"Br\u00fctting J, Steeb T, Reinhardt L, Berking C, Meier F.: Exploring the most visible german websites on melanoma immunotherapy: a web-based analysis. JMIR Cancer 2018; 4: e10676.","DOI":"10.2196\/10676"},{"key":"10.3238\/arztebl.m2024.0053_ref18","doi-asserted-by":"crossref","unstructured":"Stacey D, Legare F, Lewis K, et al.: Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017; 4: CD001431.","DOI":"10.1002\/14651858.CD001431.pub5"},{"key":"10.3238\/arztebl.m2024.0053_ref19","doi-asserted-by":"crossref","unstructured":"Elwyn G, O\u2018Connor A, Stacey D, et al.: Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 2006; 333: 417.","DOI":"10.1136\/bmj.38926.629329.AE"},{"key":"10.3238\/arztebl.m2024.0053_ref20","doi-asserted-by":"crossref","unstructured":"Joseph-Williams N, Newcombe R, Politi M, et al.: Toward minimum standards for certifying patient decision aids: a modified delphi consensus process. Med Decis Making 2014; 34: 699\u2013710.","DOI":"10.1177\/0272989X13501721"},{"key":"10.3238\/arztebl.m2024.0053_ref21","doi-asserted-by":"crossref","unstructured":"Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM: Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5\u201324.","DOI":"10.1634\/theoncologist.2010-0190"},{"key":"10.3238\/arztebl.m2024.0053_ref22","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Lo S, et al.: Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19: 672\u201381.","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"10.3238\/arztebl.m2024.0053_ref23","doi-asserted-by":"crossref","unstructured":"Hodis E, Watson IR, Kryukov GV, et al.: A landscape of driver mutations in melanoma. Cell 2012; 150: 251\u201363.","DOI":"10.1016\/j.cell.2012.06.024"},{"key":"10.3238\/arztebl.m2024.0053_ref24","doi-asserted-by":"crossref","unstructured":"Robert C, Karaszewska B, Schachter J, et al.: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30\u20139.","DOI":"10.1056\/NEJMoa1412690"},{"key":"10.3238\/arztebl.m2024.0053_ref25","doi-asserted-by":"crossref","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al.: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19: 603\u201315.","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"10.3238\/arztebl.m2024.0053_ref26","doi-asserted-by":"crossref","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, et al.: Melanoma. Lancet 2018; 392: 971\u201384.","DOI":"10.1016\/S0140-6736(18)31559-9"},{"key":"10.3238\/arztebl.m2024.0053_ref27","doi-asserted-by":"crossref","unstructured":"Bouillet T, Bigard X, Brami C, et al.: Role of physical activity and sport in oncology: scientific commission of the National Federation Sport and Cancer CAMI. Crit Rev Oncol Hematol 2015; 94: 74\u201386.","DOI":"10.1016\/j.critrevonc.2014.12.012"},{"key":"10.3238\/arztebl.m2024.0053_ref28","doi-asserted-by":"crossref","unstructured":"Grabbe P, Gschwendtner KM, Maatouk I, et al.: Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. Trials 2021; 22: 294.","DOI":"10.1186\/s13063-021-05234-4"},{"key":"10.3238\/arztebl.m2024.0053_ref29","doi-asserted-by":"crossref","unstructured":"H\u00e4rter M, Buchholz A, Nicolai J, et al.: Shared decision making and the use of decision aids. Dtsch Arztebl Int 2015; 112: 672\u20139.","DOI":"10.3238\/arztebl.2015.0672"},{"key":"10.3238\/arztebl.m2024.0053_ref30","unstructured":"Elwyn G, Grande SW, Barr P: Observer OPTION 5 Manual. Darthmouth: The Dartmouth Institute for Health Policy and Clinical Practice 2016."},{"key":"10.3238\/arztebl.m2024.0053_ref31","doi-asserted-by":"crossref","unstructured":"K\u00f6lker M, Topp J, Elwyn G, H\u00e4rter M, Scholl I: Psychometric properties of the German version of Observer OPTION(5). BMC Health Serv Res 2018; 18: 74.","DOI":"10.1186\/s12913-018-2891-6"},{"key":"10.3238\/arztebl.m2024.0053_ref32","doi-asserted-by":"crossref","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365\u201376.","DOI":"10.1093\/jnci\/85.5.365"},{"key":"10.3238\/arztebl.m2024.0053_ref33","doi-asserted-by":"crossref","unstructured":"Degner LF, Sloan JA, Venkatesh P.: The control preferences scale. Can J Nurs Res 1997; 29: 21\u201343.","DOI":"10.1037\/t22188-000"},{"key":"10.3238\/arztebl.m2024.0053_ref34","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 2010; 1: 100\u20137.","DOI":"10.4103\/0976-500X.72352"},{"key":"10.3238\/arztebl.m2024.0053_ref35","doi-asserted-by":"crossref","unstructured":"Sepucha KR, Abhyankar P, Hoffman AS, et al.: Standards for UNiversal reporting of patient Decision Aid Evaluation studies: the development of SUNDAE Checklist. BMJ Qual Saf 2018; 27: 380\u20138.","DOI":"10.1136\/bmjqs-2017-006986"},{"key":"10.3238\/arztebl.m2024.0053_ref36","doi-asserted-by":"crossref","unstructured":"van Buuren S: Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16: 219\u201342.","DOI":"10.1177\/0962280206074463"},{"key":"10.3238\/arztebl.m2024.0053_ref37","doi-asserted-by":"crossref","unstructured":"Stubenrouch FE, Pieterse AH, Falkenberg R, et al.: OPTION(5) versus OPTION(12) instruments to appreciate the extent to which healthcare providers involve patients in decision-making. Patient Educ Couns 2016; 99: 1062\u20138.","DOI":"10.1016\/j.pec.2015.12.019"},{"key":"10.3238\/arztebl.m2024.0053_ref38","unstructured":"Erdmann F, Spix C, Katalinic A, et al.: Krebs in Deutschland f\u00fcr 2017\/2018. In: Robert Koch-Institut 2021: 172. http:\/\/dx.doi.org\/10.25646\/8353 (last accessed on.4 April 2024)."},{"key":"10.3238\/arztebl.m2024.0053_ref39","doi-asserted-by":"crossref","unstructured":"Nicolai J, Moshagen M, Eich W, Bieber C: The OPTION scale for the assessment of shared decision making (PEF): methodological issues. Z Evid Fortbild Qual Gesundhwes 2012; 106: 264\u201371.","DOI":"10.1016\/j.zefq.2012.03.002"},{"key":"10.3238\/arztebl.m2024.0053_ref40","doi-asserted-by":"crossref","unstructured":"Entwistle V, Prior M, Skea ZC, Francis JJ: Involvement in treatment decision-making: its meaning to people with diabetes and implications for conceptualisation. Soc Sci Med 2008; 66: 362\u201375.","DOI":"10.1016\/j.socscimed.2007.09.001"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T12:52:57Z","timestamp":1717505577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":40,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0053","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}